US 12,252,702 B2
Recombinant poxviruses for cancer immunotherapy
Liang Deng, New York, NY (US); Jedd Wolchok, New York, NY (US); Stewart Shuman, New York, NY (US); Taha Merghoub, New York, NY (US); Ning Yang, New York, NY (US); Yi Wang, New York, NY (US); Gregory Mazo, New York, NY (US); Peihong Dai, New York, NY (US); and Weiyi Wang, New York, NY (US)
Assigned to MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
Appl. No. 17/275,974
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US)
PCT Filed Sep. 16, 2019, PCT No. PCT/US2019/051343
§ 371(c)(1), (2) Date Mar. 12, 2021,
PCT Pub. No. WO2020/056424, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/828,975, filed on Apr. 3, 2019.
Claims priority of provisional application 62/767,485, filed on Nov. 14, 2018.
Claims priority of provisional application 62/731,876, filed on Sep. 15, 2018.
Prior Publication US 2022/0056475 A1, Feb. 24, 2022
Int. Cl. C12N 15/86 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 9/0019 (2013.01); A61K 31/137 (2013.01); A61K 39/39 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07K 14/54 (2013.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/70575 (2013.01); C07K 14/71 (2013.01); C07K 16/2818 (2013.01); C12N 7/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/585 (2013.01); C12N 2710/24134 (2013.01); C12N 2710/24143 (2013.01)] 24 Claims
 
1. A modified vaccinia Ankara (MVA) virus genetically engineered to comprise a knocked out E5R gene (MVAΔE5R) and a knocked out E3L gene (ΔE3L) (MVAΔE5RΔE3L).